SWTX May 2024 50.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:19PM EDT. Market open.
| Previous close | 2.0000 |
| Open | 1.9000 |
| Bid | 0.1000 |
| Ask | 1.2500 |
| Strike | 50.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.9000 - 2.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 389 |
Simply Wall St.Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
GlobeNewswireSpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc
© 2024 Yahoo. All rights reserved.